BioSpace News Archive

LIfT BioSciences is pleased to announce that it’s lead investor, Starbloom Capital, has provided further investment into the Company to accelerate LIfT’s R&D plans and progress N-LIfT, the Company’s first-to-market anti-cancer innate cell therapy, into clinical development by Q1 2024, within 15 months after demonstrating strong preclinical results.

Kamada Ltd. today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other opportunities, effective March 15, 2023.

MediWound Ltd. today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC).

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first 50% of participants have been randomized in the Phase 3 RESILIENT study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022.

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced today that they have finalized and executed the United States Distribution Agreement (“Distribution Agreement”) for Papilocare® and Oral Immunocaps©.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt ® (iloperidone tablets), a novel atypical antipsychotic, in the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults.

Repare Therapeutics Inc. today announced that they have established new Automatic Securities Disposition Plans (“ASDPs”), or in the case of Maria Koehler modified her existing ASDP, in accordance with applicable United States and Canadian securities legislation.

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABA A Receptor Target Engagement in Healthy Volunteers.

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.